 NEW YORK, NY ACCESSWIRE March 10, 2021 Kadmon Holdings, Inc. NASDAQ:KDMN today announced that the U.S. Food and Drug Administration FDA has extended the review period for the New Drug Application NDA for belumosudil for the treatment of chronic graft-versus-host disease cGVHD. In a notice received from the FDA on March 9, 2021, the Company was informed that the Prescription Drug User Fee Act PDUFA goal date for its Priority Review of belumosudil has been extended to August 30, 2021. 